ILORASERTIB

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H21FN6O2S
Molecular Weight	488.537
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=NC=C(C2=CN(CCO)N=C2)C3=C1C(=CS3)C4=CC=C(NC(=O)NC5=CC(F)=CC=C5)C=C4

InChI

InChIKey=WPHKIQPVPYJNAX-UHFFFAOYSA-N

InChI=1S/C25H21FN6O2S/c26-17-2-1-3-19(10-17)31-25(34)30-18-6-4-15(5-7-18)21-14-35-23-20(12-28-24(27)22(21)23)16-11-29-32(13-16)8-9-33/h1-7,10-14,33H,8-9H2,(H2,27,28)(H2,30,31,34)

HIDE SMILES / InChI

Molecular Formula	C25H21FN6O2S
Molecular Weight	488.537
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT02478320 | https://www.ncbi.nlm.nih.gov/pubmed/25933833 |

Ilorasertib (previously known as ABT-348), an orally bioavailable ATP-competitive inhibitor of Aurora kinases (A, B and C), as well as the VEGF and PDGF families of receptor tyrosine kinases, was developed by AbbVie as an antineoplastic agent. It is known that Aurora kinases A, B, and C play essential roles in mitotic checkpoint control and are overexpressed by a wide variety of tumor cell types. Both VEGFRs and PDGFRs may be upregulated in various tumor cell types. Ilorasertib alone or in combination with azacitidine demonstrated activity in preclinical models in various hematological malignancies, indicating that pan-Aurora kinase and multiple kinase inhibition may have preferential antileukemic activity. Ilorasertib participated in phase I clinical for patients with advanced hematologic malignancies. The result has shown that the drug could be further studied in acute myelogenous leukemia. Ilorasertib is also going to be studied in phase II clinical trials to learn if this drug can help to control CDKN2A-deficient cancer in patients with advanced cancers.

Originator

Approval Year

PubMed

Title	Date	PubMed
Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.	2012 Dec	22935731
Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families.	2012 May 1	22465635
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.	2015 Aug	25933833
Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.	2018 Apr	29551775

Patents

Sample Use Guides

In Vivo Use Guide

Part 1 Dose of Ilorasertib: 200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle. Part 2 Expansion: Ilorasertib200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 01:29:28 GMT 2023` Edited by `admin` on `Sat Dec 16 01:29:28 GMT 2023`
Record UNII	6L5D03D975
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ILORASERTIB

Official Name

English

ILORASERTIB [USAN]

Common Name

English

Ilorasertib [WHO-DD]

Common Name

English

UREA, N-(4-(4-AMINO-7-(1-(2-HYDROXYETHYL)-1H-PYRAZOL-4-YL)THIENO(3,2-C)PYRIDIN-3-YL)PHENYL)-N'-(3-FLUOROPHENYL)-

Systematic Name

English

ABBOTT-968660

Code

English

A-968660.0

Code

English

N-(4-(4-AMINO-7-(1-(2-HYDROXYETHYL)-1H-PYRAZOL-4-YL)THIENO(3,2-C)PYRIDIN-3-YL(PHENYL)-N'-(3-FLUOROPHENYL)UREA

Common Name

English

ilorasertib [INN]

Common Name

English

ABT-348

Code

English

A-968660

Code

English

Classification Tree Code System Code

FDA ORPHAN DRUG

364212